National brain tumour research funding needs to increase to £35 million a year
Understanding whole genome sequencing webinar
There is a lack of clarity about WGS, its role in a brain tumour diagnosis and personalising ongoing treatment decisions. There is also a perception of lack of parity around access to WGS – that some centres do it and some don’t. So, what is the reality?
In this webinar, brainstrust brings key players around the table to explain more about WGS and what it means if you are living with a brain tumour. Topics covered will include:
- What WGS is and why it is important?
- Who are the key players?
- What does the wider political landscape look like now and in the future?
- How does WGS play out in the context of the neuro-oncology landscape?
- What does this mean for me if I am living with a brain tumour?
Speakers include Professor Colin Watts, Professor of Neurosurgery at the Institute of Cancer and Genomic Sciences, University of Birmingham; Associate Professor Olaf Ansorge, Lead Clinical Neuropathologist in Oxford and Director of the Thomas Willis Oxford Brain Collection; and Alona Sosinsky, Scientific Director for Cancer at Genomics England.
For more information and to reserve your spot on this free webinar, click here.
If you found this story interesting or helpful, sign up to our weekly e-news and keep up to date with all the latest from Brain Tumour Research.